Fixed‐dose combination calcipotriol/betamethasone dipropionate foam provides a rapid onset of action, effective itch relief and improves patient quality of life

The physical symptoms of psoriasis vulgaris (chronic plaque psoriasis), such as itch and itch‐related sleep loss, and the psychological impact of visible plaques on the body, all contribute to significantly reduced health‐related quality of life (HRQoL) in patients with psoriasis. In fact, the deter...

Full description

Saved in:
Bibliographic Details
Published inJournal of the European Academy of Dermatology and Venereology Vol. 35; no. S1; pp. 20 - 27
Main Authors Jalili, A., Yosipovitch, G.
Format Journal Article
LanguageEnglish
Published England John Wiley and Sons Inc 01.02.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The physical symptoms of psoriasis vulgaris (chronic plaque psoriasis), such as itch and itch‐related sleep loss, and the psychological impact of visible plaques on the body, all contribute to significantly reduced health‐related quality of life (HRQoL) in patients with psoriasis. In fact, the deterioration of HRQoL in patients with psoriasis is similar to patients with other chronic conditions, such as cancer and cardiovascular diseases. Rapid and effective improvements in HRQoL and itch‐related outcomes would therefore be highly valued by patients and may even improve adherence to treatment. In this article, we summarise previously published data assessing the impact of fixed‐dose combination calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) on itch relief, quality of sleep, onset of action and HRQoL. Findings across multiple analyses indicate that Cal/BD foam provides significant improvements in itch, itch‐related sleep loss and HRQoL compared with vehicle foam or Cal/BD gel comparators. Additionally, the benefits of Cal/BD foam were recorded earlier than these comparators, often within 1 week of treatment, indicating a rapid onset of action. With the published data to hand, it is clear that Cal/BD foam provides significant improvements in the outcomes that matter most to patients and should be considered an effective topical treatment for psoriasis. Video
Bibliography:Development of this manuscript was funded by LEO Pharma.
Conflicts of interest
Funding sources
AJ has been a consultant and advisor and/or received speaking fees and/or grants and/or served as an investigator in clinical trials for the following companies: AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, LEO Pharma, Janssen‐Cilag, MSD, Novartis, Sanofi and UCB. GY has served on scientific advisory boards for Leo Pharma, Novartis, Eli Lilly, Pfizer, Trevi, Menlo, Sanofi Regeneron, Galderma, Bellus, GSK and Kiniksa, and has been an investigator and received funds for research from Leo Pharma, Pfizer, Novartis, Kiniksa, Galderma, Sanofi Regeneron, Kiniksa and Vanda.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.17085